Consider the following medical report that includes the patient's historical health records. Use it to predict the disease that the patient is high likely exposed to. 

 Medical Report: allergies: no known allergies / adverse drug reactions attending: chief complaint: bleeding hepatic mass major surgical or invasive procedure: : angiogram with right hepatic artery embolization history of present illness: mr. is a 29 year old man, previously in good health, who reported being in usual state of health until approximately 2pm the afternoon prior to presentation. he stated that the pain was sudden in onsent and confined to his ruq. he denied any reecnt trauma to the affected area. per report, mr. pain worsened over the ensuing night, prompting him to take one percocet without much alleviation of his symptoms. he subsequently presented to lgh, where a ct abdomen was performed and demonstrated a large mass located within segment 7 of his liver. the mass was noted to be associated with a significant amount of intraabdominal fluid/blood. given this finding, he was transferred to for further care. on initial evaluation, mr. was noted to be tachycardic to 115 and hypotensive to sbp of 85, with modest improvement s/p administration of 1l crystalloid. past medical history: arf s/p ingestion of nautral diuretic product social history: bodybuilder. in school. denies t/e/d. family history: no family history of liver disease/cancer/masses physical exam: on discharge: vs: 100.2 87 139/98 18 96ra gen: walking around room, appears comfortable cv: rrr, no m/r/g, nml s1/s2 resp: ctab abd: soft, remains distended, normoactive bowel sounds, minimally tender to palpation ruq, no rebound/guarding, no ecchymoses ext: no c/c/e, alle extremities wwp pertinent results: 05:00pm blood wbc-12.5* rbc-3.44* hgb-9.8* hct-32.0* mcv-93 mch-28.6 mchc-30.7* rdw-15.0 plt ct-330 07:38pm blood wbc-11.5* rbc-2.87* hgb-8.1* hct-25.4* mcv-89 mch-28.1 mchc-31.8 rdw-14.6 plt ct-276 12:00am blood wbc-10.0 rbc-3.36* hgb-9.5* hct-30.5* mcv-91 mch-28.3 mchc-31.2 rdw-15.2 plt ct-245 03:30am blood wbc-13.0* rbc-3.44* hgb-9.7* hct-31.3* mcv-91 mch-28.4 mchc-31.1 rdw-15.4 plt ct-243 07:35am blood wbc-12.5* rbc-3.33* hgb-9.7* hct-29.3* mcv-88 mch-29.0 mchc-33.0 rdw-15.1 plt ct-226 01:31pm blood hct-30.2* 07:21pm blood hct-27.6* 05:28am blood hct-29.7* 09:00am blood hct-31.5* 03:13pm blood wbc-12.4* rbc-3.52* hgb-10.1*# hct-30.7* mcv-87 mch-28.6 mchc-32.8 rdw-15.2 plt ct-219 09:07pm blood hct-29.8* 03:10am blood wbc-9.9 rbc-3.50* hgb-10.2* hct-31.7* mcv-91 mch-29.0 mchc-32.1 rdw-15.8* plt ct-239 09:08am blood hct-28.0* 04:39pm blood hct-27.7* 06:25am blood wbc-6.4 rbc-2.96* hgb-8.6* hct-26.5* mcv-89 mch-29.1 mchc-32.5 rdw-15.6* plt ct-217 04:10pm blood wbc-8.2 rbc-3.51* hgb-9.9* hct-32.3* mcv-92 mch-28.1 mchc-30.6* rdw-16.0* plt ct-272 05:20am blood wbc-8.6 rbc-3.23* hgb-9.2* hct-29.5* mcv-91 mch-28.6 mchc-31.3 rdw-15.6* plt ct-283 05:50am blood wbc-10.1 rbc-3.45* hgb-9.8* hct-31.7* mcv-92 mch-28.3 mchc-30.8* rdw-15.3 plt ct-334 05:00pm blood pt-13.3* ptt-21.3* inr(pt)-1.2* 12:00am blood pt-13.0* ptt-21.5* inr(pt)-1.2* 03:30am blood pt-13.6* ptt-22.1* inr(pt)-1.3* 07:35am blood pt-13.6* ptt-22.1* inr(pt)-1.3* 01:31pm blood pt-13.7* ptt-22.7* inr(pt)-1.3* 01:15am blood pt-15.9* ptt-24.9* inr(pt)-1.5* 03:13pm blood pt-15.8* ptt-24.7* inr(pt)-1.5* 03:10am blood pt-15.5* ptt-25.8 inr(pt)-1.5* 05:00pm blood glucose-146* urean-29* creat-1.7* na-134 k-5.7* cl-103 hco3-22 angap-15 07:38pm blood glucose-142* urean-28* creat-1.5* na-133 k-5.9* cl-106 hco3-20* angap-13 10:43pm blood glucose-152* urean-26* creat-1.3* na-136 k-5.5* cl-108 hco3-21* angap-13 12:00am blood glucose-115* urean-26* creat-1.4* na-138 k-4.9 cl-108 hco3-22 angap-13 03:30am blood glucose-102* urean-26* creat-1.4* na-137 k-5.1 cl-106 hco3-22 angap-14 07:35am blood glucose-127* urean-25* creat-1.2 na-135 k-5.1 cl-104 hco3-23 angap-13 01:31pm blood glucose-154* urean-23* creat-1.2 na-134 k-4.8 cl-102 hco3-25 angap-12 01:15am blood glucose-153* urean-18 creat-1.0 na-133 k-4.6 cl-100 hco3-27 angap-11 03:10am blood glucose-113* urean-13 creat-0.9 na-133 k-4.4 cl-95* hco3-30 angap-12 06:25am blood glucose-138* urean-9 creat-0.8 na-133 k-3.5 cl-96 hco3-32 angap-9 05:20am blood glucose-120* urean-10 creat-0.9 na-139 k-3.7 cl-97 hco3-31 angap-15 05:50am blood glucose-83 urean-13 creat-1.0 na-134 k-4.6 cl-94* hco3-29 angap-16 05:00pm blood alt-2145* ast-1221* alkphos-89 totbili-0.7 12:00am blood alt-2375* ast-1182* alkphos-92 totbili-0.9 03:30am blood alt-3085* ast-1785* alkphos-106 totbili-1.1 07:35am blood alt-4309* ast-2569* alkphos-122 totbili-0.9 01:31pm blood alt-6770* ast-3973* alkphos-176* totbili-0.8 07:21pm blood alt-6840* ast-3906* alkphos-199* totbili-0.8 01:15am blood alt-6520* ast-3520* ld(ldh)-1687* ck(cpk)-225 alkphos-211* totbili-0.7 05:28am blood alt-5588* ast-3091* alkphos-201* totbili-1.1 03:13pm blood alt-5438* ast-2732* ld(ldh)-845* alkphos-220* totbili-1.0 03:10am blood alt-4828* ast-* ld(ldh)-618* alkphos-207* totbili-1.0 06:25am blood alt-3109* ast-894* alkphos-153* totbili-0.9 05:20am blood alt-2110* ast-511* alkphos-136* totbili-1.0 05:50am blood alt-1695* ast-335* alkphos-131* totbili-1.1 07:21pm blood hbsag-negative hbsab-positive hbcab-negative hav ab-negative igm hbc-negative igm hav-negative 07:21pm blood hcv ab-negative 05:50am blood cea-1.5 afp-1.0 05:50am blood ca -9 -pnd ct a/p: large hemorrhagic hepatic mass centered within segment vii with marked amount of adjacent subcapsular and perihepatic hematoma causing mass effect, as well as large volume hemoperitoneum. while no active arterial extravasation is seen, on the venous phase, several nodular areas of hyperdensity within the perihepatic hematoma along the anterior contour of the liver suggest sites of active bleeding. multiple other hepatic lesions are identified, some of which are isointense to the liver, and these lesions are suggestive of adenomas. angiogram and r hepatic artery embolization: angiography demonstrates displacement of the celiac axis and sma to the left, likely from large subcapsular hematoma seen on recent imaging. slightly unusual appearance of the celiac artery, likely related to significant displacement. gda appears tapered and not well visualized, likely reflecting compression. no definite active extravasation was seen on right hepatic angiography. however, marked displacement of vessels and splaying is noted, consistent with multiple masses. due to tortuosity of the vessels, angiographic opacification of peripheral intrahepatic vessels was not optimal. given this, and the patients history and clinical status, a decision to perform nonselective rha gelfoam embolizaiton was made. nonselective gelfoam embolization was performed successfully in the right hepatic artery. ruq us: patent main portal vein with patent main, right, and left hepatic arteries. kub: mildly dilated loops of small bowel with air-fluid levels, with decompressed large bowel. mri abdomen: multiple hepatic lesions most consistent with hepatic adenomas as described. the largest lesion extending from segment vi and vii has undergone hemorrhage, large subcapsular hematoma. this has not changed in extent significantly since the ct of . assessment of the hepatic vasculature is somewhat limited by non-breathhold technique, but no aberrant anatomy can be appreciated. the estimated total liver volume is 5013 cm3, although assessment is limited by the discontinous hepatic contour in the dome. brief hospital course: mr. was admitted to the hepatobiliary (west 1) surgical service on for management and evaluation of a bleeding hepatic mass. he was triaged in the ed s/p transfer from lgh. while in the ed he was aggressively fluid resuscitated given his tachycardia to 115, and was noted to be responsive to this hydration. a foley was placed for urine output monitoring, which remained more than adequate throughout his hospital stay. labs were drawn on presentation and were notable for a hct of 32. following stabilization in the ed, mr. was immediately taken to the interventional radiology suite where he underwent embolization of his r hepatic artery (reader referred to radiology note from for further details). he tolerated this procedure well. nonetheless, given concern over his potential for rebleeding as well as his persistent tachycardia, mr. was transferred to the surgical icu following his procedure for closer monitoring. neuro: the patient received iv dilaudid initially while npo. he achieved good pain control with this medication. he was transitioned to oral pain medication (oxycodone and later dilaudid) when his bowel function returned and endorsed he adequate pain control with this medication. cv: the patient was tachycardic with hr 110s on admission and immediately post ir embolization of his r hepatic artery. mr. was aggressively fluid resuscitated with both crystalloid and blood product (receiving 6u prbcs in total). he gradually responded to this therapy, and by hd#2, consistently had heart rates in the 60-80 range. mr. otherwise remained stable from a cardiovascular standpoint; vital signs were routinely monitored. pulmonary: no issues. gi: immediately post-procedure, mr. was kept npo. he was gradually transitioned from sips to clears and eventually to regular diet as he endorsed return of bowel function and adequate pain control. on hd#3, he was noted to be very distended and tympanic on physical exam, prompting a kub. the results of this study were notable for dilated loops of bowel without air-fluid levels or distinct transition point. mr. subsequently endorsed positive flatus and alleviation of his crampy abdominal pain and distention. he had no further issues re: gi function following this episode and was tolerating a regular diet by the time of discharge. id: no issues. hematology: the patient's complete blood count was examined every 4-6 hours during hd1-2. in total, mr. received 6 units of prbcs for downtrending hct. his last transfusion was on , and mr. hct was noted to remain stable in the 29-31 range on the ensuing days. prophylaxis: the patient did not receive subcutaneous heparin given his risk of recurrent bleeding. as such, venodyne boots were used during this stay; he was encouraged to get up and ambulate as early as possible. at the time of discharge, the patient was doing well, with stable vital signs. mr. was tolerating a regular diet, ambulating, voiding without assistance, and pain was well controlled. the patient received discharge teaching and follow-up instructions with understanding verbalized and agreement with the discharge plan. medications on admission: none discharge medications: 1. hydromorphone 2 mg tablet sig: one (1) tablet po q3h (every 3 hours) as needed for pain. disp:*60 tablet(s)* refills:*0* 2. lorazepam 0.5 mg tablet sig: one (1) tablet po at bedtime as needed for anxiety. disp:*30 tablet(s)* refills:*0* 3. simethicone 80 mg tablet, chewable sig: one (1) tablet, chewable po qid (4 times a day) as needed for gas pain. disp:*40 tablet, chewable(s)* refills:*0* 4. acetaminophen 325 mg tablet sig: one (1) tablet po every hours as needed for pain. 5. colace 100 mg capsule sig: one (1) capsule po twice a day. disp:*60 capsule(s)* refills:*2* 6. senna 8.6 mg capsule sig: one (1) capsule po once a day. disp:*30 capsule(s)* refills:*2* discharge disposition: home discharge diagnosis: bleeding liver masses discharge condition: mental status: clear and coherent. level of consciousness: alert and interactive. activity status: ambulatory - independent. discharge instructions: you were admitted to the hospital because of abdominal pain caused by bleeding liver masses. your blood levels (hematocrit) were closely monitored while in the icu and on the floor and you were transfused as needed. your hematocrit has been stable for several days and you have required no further blood transfusions since . you underwent a procedure, an angiogram with right hepatic artery embolization, on to help stop the bleeding within one of your liver masses. you may continue to eat a regular diet. you may continue to do aerobic exercises such as walking or riding on a stationary bike. you should not do exercises which work your core/abdominal muscles such as yoga or lifting heavy objects. you may continue with light massage as you inquired about. no deep massage to your abdomen, however. you should refrain from taking over the counter medications/natural supplements. take only the medications prescribed to you by your doctor until cleared by dr. . you should continue to drink plenty of fluids. you should not drive or operate heavy machinery while taking narcotic pain medications such as dilaudid. you may take up to 2g of tylenol a day. do not take more than this as it may damage your liver. you should continue to take senna and colace while on narcotic pain medications to avoid constipation. you should call dr. office, (, if you develop fevers, chills, worsening abdominal pain, inability to take in food or water, nausea/vomiting, worsening abdominal distention, feeling dizzy, changes in vision, lightheadedness, chest pain, shortness of breath, or any other symptom which concerns you. followup instructions: dr. : thursday at 2:30 pm procedure: injection or infusion of other therapeutic or prophylactic substance arteriography of other intra-abdominal arteries diagnoses: hyperpotassemia acute posthemorrhagic anemia acute kidney failure, unspecified hypotension, unspecified dehydration stricture of artery hemoperitoneum (nontraumatic) other specified disorders of liver 

Answer: The patient is high likely exposed to